# Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral on Danon Disease Therapy

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/28323
Published: 2026-10-08T16:47:32.000Z
Updated: 2026-10-08T16:47:32.000Z
Section: Investing

> The bank raised its rating from Sell after updates on RP-A501, Rocket Pharmaceuticals’ experimental treatment for the rare disorder Danon disease.

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral from Sell after recent updates involving RP-A501, the company’s experimental therapy for Danon disease.

Rocket Pharmaceuticals shares rose in afternoon trading Thursday, Oct. 8, following the rating change.

RP-A501 is being developed for Danon disease, a rare disorder. Rocket Pharmaceuticals is a gene therapy developer.